GlassScriptPhysician profile
Sri Mandava
NPI 1538786108
$3,448.95
in general payments reported to CMS, 2019-2025
20 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $124 · 2023: $685 · 2024: $853 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055 · Travel and Lodging: $693 · Education: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.71 |
| Travel and Lodging | $692.84 |
| Education | $470.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $911.82 | 2024-2025 | Igt Devices Undivided, (Bh4) Igt Devices Undivided |
| Medtronic, INC. | $463.61 | 2025 | Resolute Onyx, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $351.69 | 2023 | Ensite, Aveir |
| Boston Scientific Corporation | $304.67 | 2023-2024 | Avvigo Guidance System |
| Lexicon Pharmaceuticals, INC. | $166.36 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $162.99 | 2025 | |
| Chiesi USA, INC. | $155.52 | 2024 | Kengreal |
| Actelion Pharmaceuticals US, INC. | $144.86 | 2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $133.73 | 2025 | |
| Amgen INC. | $133.13 | 2024-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $124.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $88.67 | 2024 | |
| Pfizer INC. | $45.20 | 2024 | |
| Terumo Medical Corporation | $33.41 | 2023 | Tr Band, Heartrail, Angio-Seal |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $27.48 | 2023 | Renamic Neo |
| Abiomed | $26.75 | 2024 | Impella |
| Cleerly, INC. | $25.00 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Janssen Pharmaceuticals, INC | $21.74 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $21.24 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sri Mandava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.